(Reuters) – Europe’s healthcare regulator said on Wednesday it was evaluating Dexamethasone Taw as a potential COVID-19 treatment for hospitalised adult patients after it received an application from drug developer Taw Pharma. (https://bit.ly/31SOe1L)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli)
